Journal
CLINICS IN PERINATOLOGY
Volume 42, Issue 1, Pages 105-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.clp.2014.10.008
Keywords
Neonatal candidiasis; Candida; Premature infants; Risk factors
Categories
Funding
- US government [1R01HD057956-05, 1K24HD058735-05, UL1TR001117]
- Astellas Pharma
- GlaxoSmithKline
- Pfizer
- industry for neonatal and pediatric drug development
- US government (National Institute of Child Health and Human Development) [HHSN2752010000031]
Ask authors/readers for more resources
Invasive candidiasis is a leading infectious cause of morbidity and mortality in premature infants. Improved recognition of modifiable risk factors and antifungal prophylaxis has contributed to the recent decline in the incidence of this infection among infants. Invasive candidiasis typically occurs in the first 6 weeks of life and presents with nonspecific signs of sepsis. Definitive diagnosis relies on the growth of Candida in blood culture or cultures from other normally sterile sites, but this may identify fewer than half of cases. Improved diagnostics are needed to guide the initiation of antifungal therapy in premature infants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available